[
  {
    "ts": null,
    "headline": "INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus",
    "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=42c37b444cc8663bc25c1995e2224ae06bc3e494c1de9d3fbb5130415f566994",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761715868,
      "headline": "INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus",
      "id": 137248435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=42c37b444cc8663bc25c1995e2224ae06bc3e494c1de9d3fbb5130415f566994"
    }
  },
  {
    "ts": null,
    "headline": "How Investors Are Reacting To Incyte (INCY) Surging Q3 Earnings and Promising Late-Stage Trial Data",
    "summary": "Incyte Corporation recently reported third-quarter 2025 earnings well above analyst expectations, with revenue rising to US$1.37 billion and net income reaching US$424.17 million, while also presenting strong late-stage clinical trial results for key immunology and oncology assets. These developments highlight both robust demand for Incyte's current products and growing investor confidence in the company's pipeline, particularly as it prepares for new product launches and international...",
    "url": "https://finnhub.io/api/news?id=b870e5e93cfbfb1c210375b2e8485d8b3b594bc8bf83707897f1000dffa59d79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761714804,
      "headline": "How Investors Are Reacting To Incyte (INCY) Surging Q3 Earnings and Promising Late-Stage Trial Data",
      "id": 137244504,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corporation recently reported third-quarter 2025 earnings well above analyst expectations, with revenue rising to US$1.37 billion and net income reaching US$424.17 million, while also presenting strong late-stage clinical trial results for key immunology and oncology assets. These developments highlight both robust demand for Incyte's current products and growing investor confidence in the company's pipeline, particularly as it prepares for new product launches and international...",
      "url": "https://finnhub.io/api/news?id=b870e5e93cfbfb1c210375b2e8485d8b3b594bc8bf83707897f1000dffa59d79"
    }
  }
]